New Covid Variant BA.3.2 Detected Across Multiple US States
Health authorities have identified a new Covid variant, known as BA.3.2, that is spreading across the United States and may possess the ability to evade protection offered by current vaccines. The variant has been detected in nasal swabs from four American travelers and clinical samples from five patients across four unidentified states. Additionally, it has been found in three airplane wastewater samples and 132 wastewater samples collected from more than twenty states, indicating its presence is likely far more extensive than current clinical data suggests.
Origins and Global Spread of the Variant
Descended from the omicron lineage, BA.3.2 was first identified in South Africa in 2024 and subsequently appeared in the United States in June 2025 in a traveler arriving from the Netherlands. The variant experienced a significant surge beginning in September 2025 and has since been reported in twenty-three countries worldwide. Its evolutionary path mirrors that of the BA.2.86 variant, which emerged in 2024 and later evolved into JN.1, the dominant Covid strain throughout 2024.
However, researchers have issued a warning in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, stating that BA.3.2 is "genetically distinct from the JN.1 lineages that have circulated in the United States since January 2024." This genetic distinction raises concerns that current vaccines, which are tailored to target JN.1's subvariants, may require updating to maintain effectiveness against this new strain.
Genetic Mutations and Vaccine Implications
The BA.3.2 variant carries approximately seventy to seventy-five genetic changes within its spike protein, the component of the coronavirus that facilitates entry into human cells. These mutations potentially enable the virus to spread more easily and evade immune protection. Laboratory studies have demonstrated that the new strain can circumvent protective antibodies generated by existing Covid vaccines, "likely because of spike protein mutations."
Specifically, the 2025–2026 LP.8.1-adapted mRNA Covid-19 vaccine, which provides protection against predominant JN.1 strains, exhibited the lowest antibody neutralization against BA.3.2 in a laboratory study comparing seven variants. This finding highlights potential gaps in vaccine-conferred protection and underscores the need for further data on shot effectiveness.
Current Spread and Severity Assessment
BA.3.2 has been identified in twenty-five states: California, Connecticut, Florida, Hawaii, Idaho, Illinois, Maine, Maryland, Massachusetts, Missouri, New Hampshire, New Jersey, Nevada, New York, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Virginia, Wyoming, Louisiana, Michigan, and Ohio.
Despite its spread, the variant is not currently among the dominant Covid strains in the United States, according to CDC tracking data. Reported cases have not shown increased severity compared to other infections. The variant was detected in hospitalized patients during December and January in three unidentified U.S. states. These patients included two older adults with underlying health conditions and a young child who received outpatient care. All patients survived, and researchers caution that detection in hospitalized individuals "does not necessarily indicate that the variant causes more severe disease, nor does it establish any association with risk factors."
Broader Context and Public Health Outlook
With Covid now considered an endemic virus, continuous mutation is expected. Dozens of variants are currently circulating, though most undergo minimal significant change. Scientists emphasize the importance of readiness to adjust public health responses accordingly. Virologist Angela Rasmussen of the University of Saskatchewan explained to NPR last year, "Every time the virus replicates it's basically buying a couple evolutionary lottery tickets. Most of those are losers. But sometimes it hits a winner. So the key that people should think about, if they want to slow that process, is: Don't give the virus more opportunities to replicate."
This year, other respiratory illnesses such as influenza and RSV have appeared to outpace Covid during the typical winter surge. However, summer months may see another increase in cases, a pattern observed since the pandemic's onset in the United States.
While Covid-related metrics have improved—deaths have declined since last year, alongside reductions in positive tests and emergency room visits—thousands of fatalities persist. CDC data indicates there have been more than 3,600 Covid deaths recorded so far this year.
